These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28646641)

  • 21. Models for open innovation in the pharmaceutical industry.
    Schuhmacher A; Germann PG; Trill H; Gassmann O
    Drug Discov Today; 2013 Dec; 18(23-24):1133-7. PubMed ID: 23892183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can quantitative pharmacology improve productivity in pharmaceutical research and development?
    Patel M; Bueters T
    Expert Opin Drug Discov; 2020 Oct; 15(10):1111-1114. PubMed ID: 32511018
    [No Abstract]   [Full Text] [Related]  

  • 23. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
    Rossi T; Braggio S
    Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug discovery in pharmaceutical industry: productivity challenges and trends.
    Khanna I
    Drug Discov Today; 2012 Oct; 17(19-20):1088-102. PubMed ID: 22627006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endless frontier? The recent increase of R&D productivity in pharmaceuticals.
    Pammolli F; Righetto L; Abrignani S; Pani L; Pelicci PG; Rabosio E
    J Transl Med; 2020 Apr; 18(1):162. PubMed ID: 32272953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of pharma R&D productivity - a new perspective needed.
    Schuhmacher A; Hinder M; von Stegmann Und Stein A; Hartl D; Gassmann O
    Drug Discov Today; 2023 Oct; 28(10):103726. PubMed ID: 37506762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
    Danzon PM; Nicholson S; Pereira NS
    J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 34. Impact of a five-dimensional framework on R&D productivity at AstraZeneca.
    Morgan P; Brown DG; Lennard S; Anderton MJ; Barrett JC; Eriksson U; Fidock M; Hamrén B; Johnson A; March RE; Matcham J; Mettetal J; Nicholls DJ; Platz S; Rees S; Snowden MA; Pangalos MN
    Nat Rev Drug Discov; 2018 Mar; 17(3):167-181. PubMed ID: 29348681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Driving external chemistry optimization via operations management principles.
    Bi FC; Frost HN; Ling X; Perry DA; Sakata SK; Bailey S; Fobian YM; Sloan L; Wood A
    Drug Discov Today; 2014 Mar; 19(3):289-94. PubMed ID: 23973340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can governments do it better? Merger mania and hospital outcomes in the English NHS.
    Gaynor M; Laudicella M; Propper C
    J Health Econ; 2012 May; 31(3):528-43. PubMed ID: 22634021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
    Cook D; Brown D; Alexander R; March R; Morgan P; Satterthwaite G; Pangalos MN
    Nat Rev Drug Discov; 2014 Jun; 13(6):419-31. PubMed ID: 24833294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The changing structure of the pharmaceutical industry.
    Cockburn IM
    Health Aff (Millwood); 2004; 23(1):10-22. PubMed ID: 15002624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company.
    Shibayama S; Tanikawa K; Fujimoto R; Kimura H
    Drug Discov Today; 2008 Jan; 13(1-2):86-93. PubMed ID: 18190869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why and how have drug discovery strategies in pharma changed? What are the new mindsets?
    Mignani S; Huber S; Tomás H; Rodrigues J; Majoral JP
    Drug Discov Today; 2016 Feb; 21(2):239-49. PubMed ID: 26376356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.